CompletedPhase 2NCT02262130
Omalizumab in Severe and Refractory Solar Urticaria
Studying Solar urticaria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Universitaire de Besancon
- Principal Investigator
- Manuelle Viguier, MD, PhDAssistance Publique-Hôpitaux de Paris, Université Paris 7
- Intervention
- Omalizumab(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2015
Study locations (13)
- CHU de Angers, Angers, France
- Dermatology department, Centre Hospitalier Régional Universitaire, Besançon, France
- CHU de Caen, Caen, France
- CHU de Dijon, Dijon, France
- CHU de Grenoble, Grenoble, France
- CHRU de Lille, Lille, France
- CHU de Limoges, Limoges, France
- CHU de Montpellier, Montpellier, France
- CHU de Nancy, Nancy, France
- Dermatology department, Hôpital Saint-Louis, Paris, France
- CHU de Reims, Reims, France
- CHU de Rennes, Rennes, France
- CHU de Toulouse, Toulouse, France
Collaborators
Novartis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02262130 on ClinicalTrials.gov